TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search

OPHLY

Ono Pharmaceutical Co Ltd

PINKCommon Stock
$4.99
+1.42%today

No SEC filings for this security

Ono Pharmaceutical Co Ltd is a foreign or OTC-listed security (PINK) that doesn't file with the SEC, so the grounded research view — financials, filings, insider activity and the call — isn't available. Price and news only.

Key stats

52-week range$3.22 – $5.43
3.2252-week5.43
Market cap
$7.02B
Volume
2.70K
1Y return
+53.33%
Beta
0.14

Price · 1Y

$4.99▲ +53.33%
over 1Y
L $3.22H $5.43

Recent news

market news →
Deciphera Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 INTREPID Study of Sapablursen in Polycythemia VeraBullish
finance.yahoo.com· 2026-06-17
Thyroid Cancer (TC) Market View Report 2026: Ipsen/Exelixis, Ono Pharmaceutical, and Novartis Dominate the Treatment LandscapeBullish
finance.yahoo.com· 2026-05-06
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsightBullish
finance.yahoo.com· 2026-04-22
Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher TargetBullish
finance.yahoo.com· 2026-03-18
Ono Pharmaceutical (TSE:4528) Valuation Check As New Neurology And Rare Disease Partnerships AdvanceBullish
finance.yahoo.com· 2026-03-06
Sinopia Biosciences Announces Target Discovery Collaboration with Ono Pharmaceutical for Rare Metabolic DisordersBullish
finance.yahoo.com· 2026-03-03
Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New ProgramsBullish
finance.yahoo.com· 2026-03-02
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90Bullish
finance.yahoo.com· 2026-02-27

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.